Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

39.57
+0.07000.18%
Pre-market: 39.600.0300+0.08%09:10 EDT
Volume:6.18M
Turnover:245.93M
Market Cap:28.59B
PE:-84.19
High:40.45
Open:39.77
Low:39.17
Close:39.50
52wk High:42.50
52wk Low:14.50
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.79
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.76
PE(LYR):-73.28

Loading ...

Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Benzinga Earnings
·
Aug 06

Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis

Reuters
·
Aug 06

Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million

Reuters
·
Aug 06

Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million

Reuters
·
Aug 06

Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026

THOMSON REUTERS
·
Aug 06

Roivant Sciences price target raised to $35 from $31.50 at BofA

TIPRANKS
·
Jul 31

Earning Preview: Roivant Sciences Ltd. Q2 revenue is expected to decrease by 71.57%, and institutional views are cautious

Earnings Agent
·
Jul 31

Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares

Reuters
·
Jul 30

Roivant Sciences Announces Annual General Meeting of Shareholders

Reuters
·
Jul 29

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700

Reuters
·
Jul 25

Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call

Reuters
·
Jul 24

Roivant to Report Q1 Results, Host Conference Call and Webcast

Reuters
·
Jul 24

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

THOMSON REUTERS
·
Jul 24

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents

MT Newswires Live
·
Jul 16

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000

Reuters
·
Jul 03

Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76

Reuters
·
Jul 02

QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million

Reuters
·
Jul 01

Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?

Simply Wall St.
·
Jun 30